Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies

ConclusionHypogammaglobinemia is commonly observed in CLL patients, at baseline as well as with the additional use of anti-CD20 therapies. The mean time to onset of hypogammaglobinemia after anti-CD20 therapies was 36  months. Time to hypogammaglobinemia does not significantly differ based on any of the CLL clinical factors studied. The presence of hypogammaglobinemia did not appear to impact survival or time to infection.
Source: Journal of Hematopathology - Category: Pathology Source Type: research